Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

(2018) Eleonora De Martin et al.   JOURNAL OF HEPATOLOGY

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

(2018) Daniel L. Suzman et al.   LIVER INTERNATIONAL

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

(2018) Yoh Zen et al.   MODERN PATHOLOGY

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

(2017) R. A. Ibrahim et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Elevated liver enzymes in inflammatory bowel disease

(2016) Ioanna Parisi et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists

(2015) Einar S. Björnsson et al.   Clinical Gastroenterology and Hepatology

Ipilimumab in the treatment of prostate cancer

(2015) Zachary Reese et al.   Future Oncology

Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management

(2014) Roberta Elisa Rossi   WORLD JOURNAL OF GASTROENTEROLOGY

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland

(2013) Einar S. Björnsson et al.   GASTROENTEROLOGY

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

(2013) Kyung Won Kim et al.   INVESTIGATIONAL NEW DRUGS

Ipilimumab-induced acute severe colitis treated by infliximab

(2013) Cecile Pagès et al.   MELANOMA RESEARCH

Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

(2012) David E. Kleiner et al.   DIGESTIVE DISEASES AND SCIENCES

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease

(2012) Chiara van Casteren-Messidoro et al.   Journal of Crohns & Colitis

Infliximab-related hepatitis: discussion of a case and review of the literature

(2010) Stefano Mancini et al.   Internal and Emergency Medicine

Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis

(2009) David R. Minor et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells

(2009) James D. Lord et al.   DIGESTIVE DISEASES AND SCIENCES

CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues

(2008) Giao Q. Phan et al.   ANNALS OF SURGICAL ONCOLOGY

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

(2008) R. L. Johnston et al.   DIGESTIVE DISEASES AND SCIENCES